Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC) – Isaacs

jhon pablo

Editorial Commentary


John T. Isaacs1,2, W. Nathaniel Brennen1,2, Samuel R. Denmeade1,2

1Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Brady Urologic Institute, Baltimore, MD, USA;2Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence to: John T. Isaacs. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Brady Urologic Institute, Baltimore, MD, USA; Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Email: isaacjo@jhmi.edu.

Provenance: This is an invited article commissioned by the Section Editor, Dr. Peng Zhang, MD, PhD (Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, China).

Comment on: Lam HM, Nguyen HM, Labrecque MP, et al. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a

Read More